Lv1
52 积分 2023-09-21 加入
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
1个月前
已完结
MO71-4 Real-world treatment of niraparib as maintenance therapy in patients newly diagnosed advanced ovarian cancer in Japan
1个月前
已关闭
Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
1个月前
已完结
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
1个月前
已完结
[Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension]
1个月前
已完结
Orthogonal characterization of rAAV reveals vector attributes that drive ITR repair, self-complementary genome formation, and transgene expression
3个月前
已完结
Toward an age of CRISPR delivery with non-viral biologics
3个月前
已完结
Letter to Editor, International Journal of Pharmaceutics
3个月前
已完结
Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling
6个月前
已完结
皖公网安备34019202002308
